Hansa Biopharma Ab Stock Fundamentals
HNSA Stock | SEK 27.32 0.12 0.44% |
Hansa Biopharma AB fundamentals help investors to digest information that contributes to Hansa Biopharma's financial success or failures. It also enables traders to predict the movement of Hansa Stock. The fundamental analysis module provides a way to measure Hansa Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hansa Biopharma stock.
Hansa |
Hansa Biopharma AB Company Operating Margin Analysis
Hansa Biopharma's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Hansa Biopharma Operating Margin | (3.80) % |
Most of Hansa Biopharma's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hansa Biopharma AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Competition |
Based on the recorded statements, Hansa Biopharma AB has an Operating Margin of -3.7991%. This is 89.17% lower than that of the Healthcare sector and 96.61% lower than that of the Biotechnology industry. The operating margin for all Sweden stocks is 31.05% lower than that of the firm.
Hansa Biopharma AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Hansa Biopharma's current stock value. Our valuation model uses many indicators to compare Hansa Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Hansa Biopharma competition to find correlations between indicators driving Hansa Biopharma's intrinsic value. More Info.Hansa Biopharma AB is one of the top stocks in return on equity category among related companies. It is one of the top stocks in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Hansa Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Hansa Biopharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Hansa Biopharma's earnings, one of the primary drivers of an investment's value.Hansa Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hansa Biopharma's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Hansa Biopharma could also be used in its relative valuation, which is a method of valuing Hansa Biopharma by comparing valuation metrics of similar companies.Hansa Biopharma is currently under evaluation in operating margin category among related companies.
Hansa Fundamentals
Return On Equity | -0.89 | |||
Return On Asset | -0.27 | |||
Operating Margin | (3.80) % | |||
Current Valuation | 2.17 B | |||
Shares Outstanding | 52.44 M | |||
Shares Owned By Insiders | 7.37 % | |||
Shares Owned By Institutions | 41.33 % | |||
Price To Book | 7.52 X | |||
Price To Sales | 17.67 X | |||
Revenue | 154.53 M | |||
Gross Profit | 116.05 M | |||
EBITDA | (585.52 M) | |||
Net Income | (609.57 M) | |||
Cash And Equivalents | 762.73 M | |||
Cash Per Share | 19.06 X | |||
Total Debt | 783.93 M | |||
Debt To Equity | 1.60 % | |||
Current Ratio | 15.45 X | |||
Book Value Per Share | 11.55 X | |||
Cash Flow From Operations | (504.36 M) | |||
Earnings Per Share | (13.10) X | |||
Target Price | 171.0 | |||
Number Of Employees | 150 | |||
Beta | 0.88 | |||
Market Capitalization | 2.82 B | |||
Total Asset | 1.69 B | |||
Z Score | 1.8 | |||
Net Asset | 1.69 B |
About Hansa Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hansa Biopharma AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hansa Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hansa Biopharma AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Hansa Biopharma AB , a biopharmaceutical company, focuses on developing novel immunomodulatory enzymes for organ transplantation and autoimmune diseases. Hansa Biopharma AB was founded in 2001 and is headquartered in Lund, Sweden. Hansa Biopharma operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 60 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Hansa Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Hansa Biopharma's short interest history, or implied volatility extrapolated from Hansa Biopharma options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hansa Biopharma AB. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Complementary Tools for Hansa Stock analysis
When running Hansa Biopharma's price analysis, check to measure Hansa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hansa Biopharma is operating at the current time. Most of Hansa Biopharma's value examination focuses on studying past and present price action to predict the probability of Hansa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hansa Biopharma's price. Additionally, you may evaluate how the addition of Hansa Biopharma to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |